Unlocking the potential of antibody–drug conjugates for cancer therapy

JZ Drago, S Modi, S Chandarlapaty - Nature Reviews Clinical …, 2021 - nature.com
Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

The blood–tumour barrier in cancer biology and therapy

PS Steeg - Nature Reviews Clinical Oncology, 2021 - nature.com
The protective blood–brain barrier has a major role in ensuring normal brain function by
severely limiting and tightly controlling the ingress of substances into the brain from the …

Evolution of drug delivery systems: From 1950 to 2020 and beyond

H Park, A Otte, K Park - Journal of Controlled Release, 2022 - Elsevier
Modern drug delivery technology began in 1952 with the advent of the Spansule® sustained-
release capsule technology, which can deliver a drug for 12 h after oral administration …

Development of polymeric nanoparticles for blood–brain barrier transfer—strategies and challenges

W Zhang, A Mehta, Z Tong, L Esser… - Advanced …, 2021 - Wiley Online Library
Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to
treat with current drugs as their delivery efficacy to the brain is severely hampered by the …

Chemo-physical Strategies to Advance the in Vivo Functionality of Targeted Nanomedicine: The Next Generation

J Li, K Kataoka - Journal of the American Chemical Society, 2020 - ACS Publications
The past few decades have witnessed an evolution of nanomedicine from biologically inert
entities to more smart systems, aimed at advancing in vivo functionality. However, we should …

Peptide–drug conjugates with different linkers for cancer therapy

M Alas, A Saghaeidehkordi, K Kaur - Journal of medicinal …, 2020 - ACS Publications
Drug conjugates are chemotherapeutic or cytotoxic agents covalently linked to targeting
ligands such as an antibody or a peptide via a linker. While antibody–drug conjugates …

[HTML][HTML] Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy

DH Upton, C Ung, SM George, M Tsoli, M Kavallaris… - Theranostics, 2022 - ncbi.nlm.nih.gov
Despite significant advances in research, the prognosis for both primary and secondary
brain cancers remains poor. The blood-brain barrier (BBB) is a complex and unique semi …

[HTML][HTML] Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

C Fu, L Yu, Y Miao, X Liu, Z Yu, M Wei - Acta Pharmaceutica Sinica B, 2023 - Elsevier
Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after
antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability …

Peptide–drug conjugate-based novel molecular drug delivery system in cancer

YS Zhu, K Tang, J Lv - Trends in pharmacological sciences, 2021 - cell.com
Drug delivery systems are generally believed to comprise drugs and excipients. A peptide–
drug conjugate is a single molecule that can simultaneously play multiple roles in a drug …

Brain penetrating peptides and peptide–drug conjugates to overcome the blood–brain barrier and target CNS diseases

X Zhou, QR Smith, X Liu - Wiley Interdisciplinary Reviews …, 2021 - Wiley Online Library
Nearly one in six people worldwide suffer from disorders of the central nervous system
(CNS). There is an urgent need for effective strategies to improve the success rates in CNS …